Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. 薬物名(臨床試験情報から抽出) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1ANTI-VON willebrand factor nanobody, caplacizumab----1件: 64 💬
2ANTI-VON willebrand factor nanobody, INN = caplacizumab1件: Caplacizumab (Caplacizumab)1件: Caplacizumab (Caplacizumab, Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬1件: 64 💬
3Caplacizumab1件: Caplacizumab (Caplacizumab)1件: Caplacizumab (Caplacizumab, Caplacizumab, Caplacizumab-yhdp) 💬 1件: VWF 💬 8件: Complement and coagulation cascades, Coronavirus disease - COVID-19, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, Neutrophil extracellular trap formation, PI3K-Akt signaling pathway, Platelet activation 💬2件: 63, 64 💬